GH Research PLC (GHRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
GHRS Stock Price Chart Interactive Chart >
GHRS Price/Volume Stats
|Current price||$9.59||52-week high||$30.43|
|Prev. close||$9.13||52-week low||$8.72|
|Day high||$9.75||Avg. volume||96,776|
|50-day MA||$15.07||Dividend yield||N/A|
|200-day MA||$19.05||Market Cap||484.50M|
GH Research PLC (GHRS) Company Bio
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
Most Popular Stories View All
GHRS Latest News Stream
|Loading, please wait...|
GHRS Latest Social Stream
View Full GHRS Social Stream
Latest GHRS News From Around the Web
Below are the latest news stories about GH Research PLC that investors may wish to consider to help them evaluate GHRS as an investment opportunity.
DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2021 and gave updates on its business. Third Quarter 2021 Financial Results Cash position Cash was $280.7 million as of September 30, 2021, compared to $5.9 million as of December 31, 2020. Research and development e
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
Primary endpoint met in Phase 2 part of clinical trial for GH001 in TRD 7 of 8 patients (87.5%) were in remission (MADRS ≤10) at day 7 after dosing (p<0.0001) Secondary endpoints met Mean change from baseline in MADRS at day 7 after dosing was -24.4 points (-76%) (p<0.0001) GH001 was well tolerated and no serious adverse events were reported In addition, we announce positive preliminary safety results from a Phase 1 clinical pharmacology trial of GH001 in 46 healthy volunteers with 30-day follow
In this article, we examined Mark Lampert’s investment philosophy and decades of experience in the biotechnology space. We also reviewed 10 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. You can skip our detailed discussion and jump directly to 5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund. Mark […]
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided business updates and reported financial results for the second quarter ended June 30, 2021. Business Updates Corporate Updates In June 2021, we completed our initial public offering, in which we issued and sold an aggregate of 11,499,999 ordinary shares, including those issu
GHRS Price Returns